VIVUS, Inc. (VVUS) Stock Is At Yearly Low Now

October 13, 2017 - By Richard Conner

Investors sentiment increased to 1.27 in 2017 Q2. Its up 0.14, from 1.13 in 2017Q1. It increased, as 5 investors sold VIVUS, Inc. shares while 21 reduced holdings. 16 funds opened positions while 17 raised stakes. 37.61 million shares or 3.37% more from 36.39 million shares in 2017Q1 were reported.
Manufacturers Life Insurance Company The stated it has 0% in VIVUS, Inc. (NASDAQ:VVUS). Prelude Mgmt Ltd Liability Corp owns 57,400 shares for 0.01% of their portfolio. 2,500 are held by Whittier Trust Company. Spark Investment Mgmt Ltd Liability Corp reported 0.01% in VIVUS, Inc. (NASDAQ:VVUS). Financial Architects Inc holds 4,000 shares or 0% of its portfolio. Susquehanna Interest Gp Llp invested in 110,493 shares or 0% of the stock. California Employees Retirement Systems accumulated 112,000 shares or 0% of the stock. Tower Capital Limited Liability (Trc) invested in 0% or 100 shares. First Manhattan Com has 32,500 shares for 0% of their portfolio. Vanguard Group Incorporated reported 3.26 million shares or 0% of all its holdings. Gp One Trading Lp accumulated 33,397 shares or 0% of the stock. Benjamin F Edwards & Inc invested in 200 shares or 0% of the stock. Credit Suisse Ag holds 3.80 million shares. The Germany-based Deutsche National Bank Ag has invested 0% in VIVUS, Inc. (NASDAQ:VVUS). Commercial Bank Of Montreal Can holds 0% or 110,000 shares in its portfolio.

The stock of VIVUS, Inc. (NASDAQ:VVUS) hit a new 52-week low and has $0.77 target or 9.00 % below today’s $0.85 share price. The 7 months bearish chart indicates high risk for the $89.97 million company. The 1-year low was reported on Oct, 13 by If the $0.77 price target is reached, the company will be worth $8.10M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 633,435 shares traded. VIVUS, Inc. (NASDAQ:VVUS) has declined 7.14% since October 13, 2016 and is downtrending. It has underperformed by 23.84% the S&P500.

Analysts await VIVUS, Inc. (NASDAQ:VVUS) to report earnings on November, 8. They expect $-0.13 EPS, down 44.44 % or $0.04 from last year’s $-0.09 per share. After $-0.13 actual EPS reported by VIVUS, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

VIVUS, Inc. (NASDAQ:VVUS) Ratings Coverage

Among 2 analysts covering Vivus (NASDAQ:VVUS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vivus had 3 analyst reports since July 31, 2015 according to SRatingsIntel. As per Thursday, November 5, the company rating was upgraded by WallachBeth Capital. The rating was maintained by RBC Capital Markets on Friday, July 31 with “Outperform”. The firm earned “Hold” rating on Wednesday, August 5 by Zacks.

VIVUS, Inc. is a biopharmaceutical company. The company has market cap of $89.97 million. The Firm operates in the development and commercialization of therapeutic products segment. It has a 2.8 P/E ratio. It provides over two therapies approved by the Food and Drug Association , which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.